Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BioPharma Credit's enterprise value is $1,075.9 Mil.
BioPharma Credit's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $129.9 Mil. Therefore, BioPharma Credit's EV-to-EBITDA for today is 8.28.
The historical rank and industry rank for BioPharma Credit's EV-to-EBITDA or its related term are showing as below:
LSE:BPCR's EV-to-EBITDA is not ranked *
in the Asset Management industry.
Industry Median: 9.23 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioPharma Credit's PE Ratio (TTM) for today is calculated as:
BioPharma Credit's share price for today is $0.97.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioPharma Credit's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.114.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for BioPharma Credit's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, BioPharma Credit's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioPharma Credit EV-to-EBITDA vs Asset Management Industry
For the Asset Management industry and Financial Services sector, BioPharma Credit's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BioPharma Credit's EV-to-EBITDA falls into.
BioPharma Credit's current Enterprise Value is $1,075.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioPharma Credit's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $129.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioPharma Credit (LSE:BPCR) has a EV-to-EBITDA of 8.28 as of Sep. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BioPharma Credit. According to the industry distribution chart, BioPharma Credit ranks #999999 out of 874 companies in the Asset Management industry.
Is BioPharma Credit's EV-to-EBITDA too high?
BioPharma Credit's current EV-to-EBITDA is 8.28. The Asset Management industry median EV-to-EBITDA is 9.23. BioPharma Credit's value of 8.28 is 10.3% below this industry median. Based on the distribution chart, BioPharma Credit ranks #999999 out of 874 companies in the Asset Management industry, which is in the bottom quartile relative to peers. Overall, BioPharma Credit has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's EV-to-EBITDA compare to BLK and BX?
According to the Asset Management industry distribution chart, BioPharma Credit ranks #999999 out of 874 companies for EV-to-EBITDA. This places BioPharma Credit in the lower half of its industry. The industry median EV-to-EBITDA is 9.23. BioPharma Credit's value of 8.28 is 10.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for an Asset Management company?
The median EV-to-EBITDA among Asset Management companies is 9.23, based on 874 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioPharma Credit's current EV-to-EBITDA of 8.28 is 10.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BioPharma Credit. For the Asset Management industry, the median EV-to-EBITDA is 9.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioPharma Credit's current EV-to-EBITDA is 8.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.82, compared to a current price of $0.97 — trading 18.3% above its estimated fair value. The current EV-to-EBITDA is 8.28 and 10.3% below the Asset Management industry median of 9.23. BioPharma Credit's overall GF Score™ is 46/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current EV-to-EBITDA is 8.28 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?
Based on GuruFocus' analysis, BioPharma Credit stock appears to be overvalued.
The current stock price of $0.97 is trading 18.3% above its estimated GF Value™ of $0.82.
GuruFocus considers BioPharma Credit to be Modestly Overvalued.
Key valuation signals for LSE:BPCR:
EV-to-EBITDA: 8.28
GF Value™: $0.82 vs. price of $0.97 (18.3% above fair value)
Industry Position: 10.3% below the Asset Management median (#999999 of 874)
No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
46GF Score
Get the complete analysis for LSE:BPCR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BPCR has been successfully added to your 
